{"id":267318,"date":"2026-09-24T12:17:56","date_gmt":"2026-09-24T06:47:56","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=267318"},"modified":"2026-09-24T12:20:23","modified_gmt":"2026-09-24T06:50:23","slug":"metropolis-healthcare-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/metropolis-healthcare-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Metropolis Healthcare Q2 Results: Can the Volume-Led Growth Streak Continue?"},"content":{"rendered":"
Metropolis Healthcare Q1 FY27 consolidated revenue Rs 450 crore (+16.6% YoY), consolidated PAT Rs 56.7 crore (+25.7% YoY). Q2 FY26 base: PAT Rs 53 crore (+13% YoY).<\/div>\n
\n

Quick Answer<\/strong><\/p>\n

Metropolis Healthcare’s Q2 results FY27 date is not confirmed. Q1 FY27 (June 2026 quarter) consolidated net profit rose 25.72% YoY to Rs 56.7 crore on revenue of Rs 450 crore, up 16.58% YoY, with EBITDA margin expanding 145 basis points to 24.7% – growth achieved entirely through higher patient and test volumes without any price increases. The Q2 FY27 print will be compared against a Q2 FY26 base where profit had already grown 13% YoY to Rs 53 crore.<\/p>\n<\/div>\n

The Metropolis Healthcare<\/a> Q2 results FY27 print is the next earnings event for India’s second-largest pathology laboratory chain, which has been expanding into Tier 2 and Tier 3 cities through organic growth and acquisitions.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n